An interventional study of Anticancer Learning Circle in Neoplasm, Uterine, sponsored by University of Virginia. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-24.
Sponsored by University of Virginia · Not applicable, Interventional, and Supportive care
The purpose of this study is to promote positive lifestyle change among endometrial cancer survivors by using a group-based intervention. Endometrial cancer survivors are at an increased risk of other health conditions like heart disease, diabetes, and other cancers. The study team at the University of Virginia wants to explore new ways to lower these risks. This study will be evaluating the Anticancer Lifestyle program, which takes a more holistic approach and uses web-based learning modules along with weekly group sessions to discuss each topic of the web-based learning modules.
255 studies on the registry are indexed under Uterine Neoplasms; 64 are open to participants now.
This study's enrollment of 23 is below the median of 49 across 181 interventional studies indexed under Uterine Neoplasms.
Browse Uterine Neoplasms studies →University of Virginia is the lead sponsor of 653 studies on the registry; 134 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 41 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Behavioral: Anticancer Learning Circle
All participants will partake in the Anticancer Learning Circle, a lifestyle modification program. All participants will complete web-based learning modules focused on improving diet, lowering stress, increasing fitness, and reducing exposure to toxins in the home environment. Each week, all participants will meet as a group to discuss the learning topic of the web-based learning module for the week.
Number of participants that complete the program
The proportion of participants completing the program as defined by the number of those who participated in at least 75% of online sessions.
Time frame: Week 7
Change from Week 0 of the Automated Self-administered 24-hour Dietary Assessment (ASA24) at Week 7
The Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool is a free, web-based tool created by the National Cancer Institute to assess nutritional intake. ASA24 enables multiple, automatically coded, self-administered 24-hour diet recalls and/or single or multi-day food records, also known as food diaries. Overall nutrition will be assessed at week 0 and week 7 to compare and evaluate changes in dietary patterns of participants.
Time frame: 7 weeks
Change from Week 0 of Generalized Anxiety Disorder (GAD-7) Survey from Baseline at Week 32
The GAD-7 is a validated, self-reported survey assessing feelings of anxiety. Possible scores range from 0 (minimal anxiety) to 21 (severe anxiety). Scores will be evaluated at weeks 0, 4, 7, and 32 with overall primary endpoint evaluating change between week 0 and week 32. Change = (Week 32 Score - Week 0 score)
Time frame: 32 weeks
Change from Week 0 of the Godin Leisure-Time Exercise Questionnaire (GLTEQ) from Baseline at Week 32
The GLTEQ is a validated, self-reported scale assessing physical activity. Participants self-report the number of times per week they engage in strenuous, moderate, and mild/light physical activity. The self-reported number is multiplied by 9 for strenuous exercise, 5 for moderate exercise, and 3 for mild/light exercise. Scores can range from less than 14 units (insufficiently Active/Sedentary) to 24 units of more (Active). Scores will be evaluated at weeks 0, 4, 7, and 32 with overall primary endpoint evaluating change between week 0 and week 32. Change = (Week 32 score - Week 0 score)
Time frame: 32 weeks
Change from Week 0 of the Cancer Worry Scale (CWS) to Week 32
The CWS scale is a validated, self-reported scale assessing participants worries about developing or reoccurring cancer. Scores can range from 8 (seldom or never worried) to 32 (worried a lot/almost all the time). Scores will be evaluated at weeks 0, 4, 7, and 32 with overall primary endpoint evaluating change between week 0 and week 32. Change = (Week 32 score - Week 0 score)
Time frame: 32 weeks
Change from Week 0 of the Patient Health Questionnaire (PHQ-9) to Week 32
The PHQ-9 is a validated, self-reported scale to assess symptoms of major depressive disorder. Scores can range from 0 (none-Minimal) to 27 (severe). Scores will be evaluated at weeks 0, 4, 7, and 32 with overall primary endpoint evaluating change between week 0 and week 32. Change = (Week 32 score - Week 0 score)
Time frame: Baseline and Week 32
Assess Attitudes Toward Group-Based Lifestyle Therapy Program Utilizing Internal Scale at Week 7 and Week 32
Internal survey built to evaluate participants' satisfaction with the Anticancer Lifestyle Foundation's lifestyle program. Quantitative measures are gathered utilizing a scale of Strongly Disagree to Strongly Agree to assess participant attitudes towards program satisfaction, usefulness of information learned, and to gauge if the participant feels they were able to make positive lifestyle changes through participation in the program. Additional questions assess feelings towards preferences of group size, platform used, number of sessions, and length of program. Qualitive measure allows participants to share any thoughts/concerns/or feedback regarding the program.
Time frame: Week 7 and Week 32
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Virginia